Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
tipifarnib
Description:
Tipifarnib is a small-molecule farnesyltransferase inhibitor investigated as a targeted anticancer drug.
Primary topic:
Acute Myeloid Leukemia Research (21%)
Related topics:
Acute Myeloid Leukemia Research (21%),
Protein Kinase Regulation and GTPase Signaling (8%)
Wikidata ID:
wiki/Q7808830
OpenAlex ID:
keywords/tipifarnib
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
2004
·
E. Van Cutsem
, H. van de Velde
, et al.
·
Journal of Clinical Oncology
·
850
High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer
2018
·
Amrita Datta
, Hogyoung Kim
, et al.
·
Scientific Reports
·
314
PDF
The incidence and impact of thrombocytopenia in myelodysplastic syndromes
2007
·
Hagop Kantarjian
, Francis Giles
, et al.
·
Cancer
·
263
PDF
Tipifarnib in Head and Neck Squamous Cell Carcinoma WithHRASMutations
2021
·
Alan L. Ho
, Irene Brana
, et al.
·
Journal of Clinical Oncology
·
237
PDF
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model
2008
·
Brian C. Capell
, Michelle Olive
, et al.
·
Proceedings of the National Academy of Sciences
·
230
Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient
2020
·
Hye Won Lee
, Woosung Chung
, et al.
·
Genome Medicine
·
215
PDF
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
2006
·
Jeffrey E. Lancet
, Ivana Gojo
, et al.
·
Blood
·
192
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
2004
·
M. Alsina
, Rafael Fonseca
, et al.
·
Blood
·
187
Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay
2021
·
Woo Dae Jang
, Sangeun Jeon
, et al.
·
Proceedings of the National Academy of Sciences
·
184
Treatment of high-grade glioma in children and adolescents
2011
·
T. J. MacDonald
, D. Aguilera
, et al.
·
Neuro-Oncology
·
172
PDF
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
2009
·
Jean-Luc Harousseau
, Giovanni Martinelli
, et al.
·
Blood
·
165
PDF
Rational Modification of a Candidate Cancer Drug for Use Against Chagas Disease
2009
·
James M. Kraus
, Christophe L. M. J. Verlinde
, et al.
·
Journal of Medicinal Chemistry
·
165
Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
2006
·
Timothy F. Cloughesy
, Patrick Y. Wen
, et al.
·
Journal of Clinical Oncology
·
163
Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas
2006
·
Brigitte C. Widemann
, Wanda L. Salzer
, et al.
·
Journal of Clinical Oncology
·
154
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
2007
·
Mitch Raponi
, Jeffrey E. Lancet
, et al.
·
Blood
·
147
Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis
2022
·
Liusheng Wu
, Yanfeng Zhong
, et al.
·
Biomedicines
·
142
PDF
Tipifarnib as a Precision Therapy for HRAS -Mutant Head and Neck Squamous Cell Carcinomas
2020
·
Mara Gilardi
, Zhiyong Wang
, et al.
·
Molecular Cancer Therapeutics
·
131
PDF
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas
2014
·
B. C. Widemann
, E. Dombi
, et al.
·
Neuro-Oncology
·
127
Second Generation Analogues of the Cancer Drug Clinical Candidate Tipifarnib for Anti-Chagas Disease Drug Discovery
2010
·
James M. Kraus
, Hari Babu Tatipaka
, et al.
·
Journal of Medicinal Chemistry
·
123
Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways
2003
·
Herbert B Newton
·
Expert Review of Anticancer Therapy
·
122
Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies
2011
·
David S. Hong
, Maria E. Cabanillas
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
116
Advances in paediatric cancer treatment.
2014
·
Federica Saletta
, Michaela S Seng
, et al.
·
PubMed
·
113
MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC)
2011
·
T. Y. Poussaint
, M. Kocak
, et al.
·
Neuro-Oncology
·
112
PDF
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
2007
·
Pierre Fenaux
, Azra Raza
, et al.
·
Blood
·
111
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas
2014
·
Brigitte C. Widemann
, Dusica Babovic-Vuksanovic
, et al.
·
Pediatric Blood & Cancer
·
107
Show more works
View as search
Works count:
657
Citation count:
13,180
Year
Topic
Type